Black checkmark with a sparkle and a curved line underneath on a white background.
Company

SCIENTIFIC INDUSTRIES INC

Ticker
SCND
Sector
Industry
Report date
November 13, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent news coverage includes general market and sector developments but no direct recent news about Scientific Industries’ business activities.

Recent developments:
  • Recent news includes discussion of the AI sector and IPOs, commodity market updates, and earnings summaries of other companies, but no direct news on Scientific Industries [N1].
  • No recent company-specific announcements or developments were identified in the latest news coverage [N2][N3][N4][N5][N6].
Overview

Scientific Industries, Inc. is a manufacturer and marketer of benchtop laboratory equipment and bioprocessing systems. The company operates through two segments: Benchtop Laboratory Equipment, which includes balances, scales, pill counters, and moisture analyzers marketed under Torbal and VIVID brands; and Bioprocessing Systems, which offers products incorporating smart sensors and software analytics under the DOTS brand. The company designs most products in-house and sells through direct sales forces and distributors primarily in the US, Europe, and Asia. It sold its Genie product line in 2025 but continues other product lines. The company holds patents protecting key products and invests heavily in research and development, particularly in bioprocessing. It maintains production facilities in New York and Germany. The company faces competition from larger firms and operates in a market with no material seasonality or backlog. Financially, it reported revenues of $1.35 million and net income of $470,000 for the quarter ended September 30, 2026, with strong liquidity ratios. However, it has a history of operating losses and an accumulated deficit, reflecting ongoing investment in growth and development.

Executive summary

Scientific Industries, Inc. operates two main segments: Benchtop Laboratory Equipment and Bioprocessing Systems. The company designs and manufactures laboratory equipment and bioprocessing products primarily for research use. It sold its Genie product line in 2025 but continues to market scales and pill counters. The Bioprocessing Systems segment involves advanced products with smart sensors and software analytics. The company invests significantly in R&D, especially in bioprocessing. Financially, as of September 30, 2026, it reported $1.35 million in revenue, $470,000 net income, and strong liquidity ratios (current ratio 6.43, cash ratio 4.4). The company has a history of operating losses and faces risks related to funding and market liquidity. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for SCND

Bull case model:

The company’s significant investment in bioprocessing systems and product development could enhance its position in a specialized market segment with advanced technology products. Its strong liquidity position as of September 2026 supports ongoing operations and development efforts. The patent portfolio provides protection for key products, potentially supporting sustained revenue streams. The company’s diversified product lines and geographic sales exposure, including international markets, may provide growth opportunities.

Bear case model:

The company has a history of operating losses and an accumulated deficit, reflecting challenges in achieving sustained profitability. The sale of the profitable Genie product line reduces revenue sources, and the remaining Benchtop Laboratory Equipment segment is not yet profitable. The company’s reliance on a limited number of major customers and distributors presents concentration risks. Funding constraints and the need for additional capital to support product development and commercialization pose financial risks. The thinly traded stock and ownership concentration may limit market liquidity and increase volatility.

Moat:

Scientific Industries holds patents on key products such as the VIVID automated pill counter and multiple bioprocessing technologies, providing intellectual property protection through at least 2036-2039. The company’s in-house product design and development capabilities, combined with specialized bioprocessing products incorporating smart sensors and software analytics, contribute to differentiation. Its established distribution networks, including exclusive distributors for certain products and a direct sales force for bioprocessing systems, support market access. However, the company faces competition from larger firms with greater resources, which may limit its competitive moat.

Risks overview
Risks summary
The primary risks relate to the company’s limited financial resources and funding needs, ongoing operating losses, customer concentration, competitive pressures, and stock liquidity challenges.
Risks details:

• Limited Financial Resources and Funding Needs: The company may need to raise additional capital to fund product development and commercialization, especially in the bioprocessing segment. Failure to secure adequate funding could delay or reduce development efforts and impact financial condition [S1].
• Operating Losses and Profitability Challenges: Historical operating losses and an accumulated deficit indicate ongoing challenges in achieving and sustaining profitability. The sale of profitable product lines and unprofitable remaining segments add to this risk [S1].
• Customer and Vendor Concentration: A significant portion of revenue depends on a single major customer and a limited number of vendors, which could impact sales and supply chain stability if relationships change [S1].
• Market Competition: The company faces competition from larger firms with greater financial and marketing resources, which may affect market share and pricing [S1].
• Stock Liquidity and Volatility: The company’s common stock is thinly traded with significant ownership concentration, potentially leading to price volatility and limited liquidity for shareholders [S1].

FINAL FORECAST FOR SCND

Final take one line
Scientific Industries has detailed disclosures on its laboratory and bioprocessing equipment business with strong liquidity but faces risks from funding needs and profitability challenges.
Final take 12 to 24 month view

Business trends: Continued investment in bioprocessing product development and focus on specialized laboratory equipment segments.
Execution milestones: Ongoing commercialization of Bioprocessing Systems products, maintaining strong liquidity, and managing divestiture impacts.
Key risks: Funding constraints, operating losses, customer concentration, competitive pressures, and limited stock liquidity.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Scientific Industries, Inc. is a Delaware corporation incorporated in 1954 engaged in design, manufacture, and marketing of benchtop laboratory equipment and bioprocessing systems through its wholly-owned subsidiary Scientific Bioprocessing Holdings, Inc. (SBHI) and its subsidiaries Scientific Bioprocessing, Inc. and aquila biolabs GmbH [S1].
  • The company operates two segments: Benchtop Laboratory Equipment (including weighing instruments, pill counters, and scales) and Bioprocessing Systems (products with smart sensors and software analytics) [S1].
  • On August 7, 2025, the company sold its Genie product line (part of Benchtop Laboratory Equipment) to Troemner, LLC for $9.6 million plus earn-out, continuing to produce scales and pill counters [S1].
  • Benchtop Laboratory Equipment products include Torbal and VIVID branded balances, scales, force gauges, automated pill counters, and moisture analyzers sold primarily online and through distributors [S1].
  • Bioprocessing Systems products include Cell Growth Quantifier (CGQ), Liquid Injection System (LIS), coaster systems, flow-through cells for pH and DO monitoring, Multi-Parameter Sensor (MPS), and Dissolved Oxygen sensor pills marketed under the DOTS brand [S1].
  • The company designs and develops substantially all products in-house, with outside consultants augmenting engineering capabilities. Significant investment is made in Bioprocessing Systems product development [S1].
  • Major customers include one customer representing 31% of consolidated net revenues in 2025, mainly for VIVID Pill counters [S1].
  • The company markets Benchtop Laboratory Equipment primarily online and through two exclusive distributors in North America; Bioprocessing Systems are marketed through a direct sales force and a network of 11 distributors in the US and Germany [S1].
  • Production facilities are located in Bohemia and Pearl River, New York for Benchtop Laboratory Equipment, and Baesweiler, Germany for Bioprocessing Systems [S1].
  • The company holds patents for its VIVID automated pill counter (expiring 2039) and multiple patents for bioprocessing products held by Aquila subsidiary expiring between 2036 and 2038, with additional patents pending [S1].
  • Foreign sales accounted for approximately 17% of net revenue in 2025, mainly in Asia and Europe, with payments primarily in USD [S1].
  • The company does not consider its business materially seasonal and does not have a material backlog of orders due to short production and shipping times [S1].
  • Competition includes larger companies with greater resources; direct competitors for Benchtop products include Ohaus, A&D Company, Adam Equipment, Illinois Tool Works, Capsa Healthcare, and Medility; for Bioprocessing Systems, competitors include ABER Instruments, PreSens GmbH, Hamilton Bonaduz AG, optek-Danulat GmbH, Sartorius AG, and Eppendorf SE [S1].
  • Research and development expenses were $2.49 million in 2025, mainly for Bioprocessing Systems, with continued material R&D expenditures anticipated [S1].
  • The company’s products do not require FDA or other governmental approval; manufacturing operations comply with environmental and safety regulations [S1].
  • As of March 31, 2026, the company employed 55 persons, with 21 in Benchtop Laboratory Equipment and 34 in Bioprocessing Systems, mostly in Europe [S1].
  • Financial snapshot as of 2026-09-30 shows cash and equivalents of $515,400, current assets of $8,495,800, current liabilities of $1,321,700, revenue of $1,354,800, net income of $470,000, and diluted EPS of $0.04 [S2].
  • Liquidity ratios as of 2026-09-30 include a current ratio of 6.43 and a cash ratio of 4.4, indicating strong short-term liquidity [S2].
  • The company has a history of operating losses with net losses of $1.22 million in 2025 and $6.45 million in 2024, with an accumulated deficit of $35.15 million as of December 31, 2025. The Bioprocessing Systems segment is expected to incur expenses exceeding revenues for the foreseeable future [S1].
  • The company sold its profitable Genie Division in August 2025; the remaining Torbal division is not yet profitable [S1].
  • The company faces risks related to limited financial resources and the need to raise additional funding to support product development and commercialization, especially in bioprocessing [S1].
  • The company’s common stock is thinly traded on the OTC Bulletin Board with significant ownership concentration among three largest shareholders, leading to potential volatility and liquidity risks [S1].
  • Recent news coverage includes general market and sector news but no direct recent news about Scientific Industries’ business developments [N1][N2][N3][N4][N5][N6][N7][N8].
Sources
Sources - Context summary

Generated 2026-11-14

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-31 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-11-14 | www.nasdaq.com | Can the Anthropic IPO Save the AI Rally? | https://www.nasdaq.com/articles/can-anthropic-ipo-save-ai-rally
  • N2 | 2026-11-14 | www.nasdaq.com | Lucara Diamond Corp. Q3 Earnings Summary | https://www.nasdaq.com/articles/lucara-diamond-corp-q3-earnings-summary
  • N3 | 2026-11-14 | www.nasdaq.com | Crown Point Energy Inc Q3 Loss Narrows | https://www.nasdaq.com/articles/crown-point-energy-inc-q3-loss-narrows
  • N4 | 2026-11-14 | www.nasdaq.com | Corn Firm into the Weekend as Export Business Picks Up | https://www.nasdaq.com/articles/corn-firm-weekend-export-business-picks
  • N5 | 2026-11-14 | www.nasdaq.com | Soybeans Post Friday Gains Following Export Announcements | https://www.nasdaq.com/articles/soybeans-post-friday-gains-following-export-announcements
  • N6 | 2026-11-14 | www.nasdaq.com | Hogs Post Gains Across the Board on Friday | https://www.nasdaq.com/articles/hogs-post-gains-across-board-friday
  • N7 | 2026-08-17 | www.nasdaq.com | 3 Reasons to Claim Social Security at 62 | https://www.nasdaq.com/articles/3-reasons-claim-social-security-62
  • N8 | 2026-08-17 | www.nasdaq.com | Alphabet's Reported $112 Billion Profit Included a $94 Billion Paper Gain From SpaceX. Here's What the Company Actually Earned. | https://www.nasdaq.com/articles/alphabets-reported-112-billion-profit-included-94-billion-paper-gain-spacex-heres-what
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine